Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sciences Renames Its Subsidiary Lab to Enhance Vertical Integration

NEW YORK, June 18 - DNA Sciences has changed the name of its wholly-owned subsidiary PPGx laboratories to DNA Sciences Laboratories in an effort to create vertical integration, the company said Monday. 

The lab's products and services will continue to be marketed exclusively through the laboratory. The Morrisville, NC-headquartered lab also has locations in La Jolla, Calif., Cambridge, Mass., and Cambridge, UK. The labs conduct clinical genotyping, assay development and validation, target validation, allele frequency determination, and polymorphism discovery.

"Our goal is to cultivate a unified identity for DNA Sciences across the spectrum of our business activities, including clinical support services and research collaborations that seek to identify genetic variants involved in treatment response," Hugh Rienhoff, CEO of DNA Sciences, said in a statement. "In addition, DNA Sciences Laboratories enables commercialization of products resulting from our own discovery efforts. As genetics becomes integrated into the drug discovery and development process, we anticipate our clinical laboratories business to grow aggressively." 

DNA Sciences studies the role genes play in diseases such as cancer, asthma, and diabetes. It is also planning to commercialize diagnostic tests.  
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.